RALEIGH, North Carolina–(BUSINESS WIRE)–Veranex, the only truly comprehensive, global technology services provider dedicated to the MedTech industry, today announced the appointment of industry veteran Tom Daulton as Chief Executive Officer (CEO). David Dockhorn, who previously held this position, assumes the newly created role of chief operating officer (COO).
Tom Daulton brings more than 30 years of healthcare leadership experience to Veranex from National Dentex Labs (NDX), where he served as President and CEO for the past seven years and built the one of the largest networks of dental laboratories in North America. His additional experience includes key roles in medical device and healthcare services organizations globally, including 20 years with Baxter, Allegiance Healthcare and Cardinal Health. Daulton was also founder and CEO of Devicor Medical Products, which acquired Mammotome’s breast care business from Johnson & Johnson’s Ethicon Endo-Surgery. The addition of Daulton will further expand the extended device experience in the Veranex Executive Suite.
“I am thrilled to join this exceptional team and to continue the progress that David has already championed,” said Daulton. “As an end-to-end MedTech service provider, Veranex is clearly poised for an exciting future. My background – including the experience of building two major global healthcare companies – has given me a strong understanding of how to bind a variety of cultures into one powerful, unified company. I look forward to working closely with the team to strengthen Veranex’s role as a leader in MedTech innovation, delivering end-to-end solutions to our customers and continuing to raise the industry standard in quality and speed to market.
In his new role as COO, David Dockhorn will focus on operational excellence as Veranex continues its global expansion through both acquisition-driven and organic growth. He will support Daulton in integrating the business and building the organizational structure needed to support Veranex’s growing global footprint.
“I’m proud of the business we’re building and the impact we have with our customers every day,” Dockhorn said. “Our global team has worked to create a business that uniquely addresses the full spectrum of MedTech customer needs – from medical device discovery through invention, manufacturing, preclinical, clinical/regulatory, market launch and – enabling our clients to work at scale. I am excited to strengthen our impact by focusing on building operational teams that support organic growth as we continue to build our capabilities and improve our operations, while Tom focuses on leading the organization and helping it grow.
“The Veranex Board of Directors is delighted to welcome Tom to lead the company through this next stage of growth,” said Veranex Chairman of the Board. Patrick Donnelly. “Tom is a proven leader with deep experience in medical technologies and leading global companies. His experience, combined with David’s operational leadership expertise, allows Veranex to deepen our ability to help our customers deliver innovations that have a real impact on the lives of patients everywhere.
Veranex is the only truly comprehensive, global, technology-based service provider dedicated to the MedTech industry. Offering expert guidance from concept to market and across the development continuum, Veranex helps accelerate time to market, control development costs, mitigate development risk, and accelerate development. assessment of market viability. At every step, Veranex customers save time and money, while its comprehensive solutions unify and streamline the entire development process. Veranex is backed by Summit Partners, Acceleratedand Lauxera Capital Partners. For more information, visit VeranexSolutions.com and follow Veranex on LinkedIn.